Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Interest Expenses (2020 - 2025)

Rani Therapeutics Holdings has reported Interest Expenses over the past 6 years, most recently at $347000.0 for Q4 2025.

  • Quarterly results put Interest Expenses at $347000.0 for Q4 2025, down 69.13% from a year ago — trailing twelve months through Dec 2025 was $2.9 million (down 42.52% YoY), and the annual figure for FY2025 was $2.9 million, down 42.56%.
  • Interest Expenses for Q4 2025 was $347000.0 at Rani Therapeutics Holdings, down from $725000.0 in the prior quarter.
  • Over the last five years, Interest Expenses for RANI hit a ceiling of $1.3 million in Q3 2024 and a floor of -$1000.0 in Q4 2021.
  • Median Interest Expenses over the past 5 years was $910000.0 (2025), compared with a mean of $808055.6.
  • Biggest five-year swings in Interest Expenses: tumbled 101.72% in 2021 and later soared 72000.0% in 2022.
  • Rani Therapeutics Holdings' Interest Expenses stood at -$1000.0 in 2021, then soared by 72000.0% to $719000.0 in 2022, then soared by 80.25% to $1.3 million in 2023, then decreased by 13.27% to $1.1 million in 2024, then plummeted by 69.13% to $347000.0 in 2025.
  • The last three reported values for Interest Expenses were $347000.0 (Q4 2025), $725000.0 (Q3 2025), and $877000.0 (Q2 2025) per Business Quant data.